Morgan Stanley analyst Judah Frommer assumed coverage of Blueprint Medicines (BPMC) with an Equal Weight rating and price target of $120, up ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback